Zylox-Tonbridge Medical Technology Co (FRA:818) Total Equity: €391.6 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:818 Zylox-Tonbridge Medical Technology Co Ltd FRA:818
76 GF Score
Price €2.08
GF Value €3.72
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Zylox-Tonbridge Medical Technology Co Total Equity?

Zylox-Tonbridge Medical Technology Co FRA:818 -2.80% 76 Total Equity is €391.6 Mil as of Dec. 2025. GuruFocus rates FRA:818 with a GF Score™ of 76/100 and a GF Value™ of €3.72 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Zylox-Tonbridge Medical Technology Co's total equity for the quarter that ended in Dec. 2025 was €391.6 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Zylox-Tonbridge Medical Technology Co Total Equity Historical Data

* Premium members only.

The historical data trend for Zylox-Tonbridge Medical Technology Co's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zylox-Tonbridge Medical Technology Co Total Equity Chart

Zylox-Tonbridge Medical Technology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 436.95 418.96 391.37 406.76 391.62

Zylox-Tonbridge Medical Technology Co Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 391.37 398.20 406.76 380.91 391.62
FRA:818
76GF Score
Zylox-Tonbridge Medical Technology Co Ltd FRA:818
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zylox-Tonbridge Medical Technology Co Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Zylox-Tonbridge Medical Technology Co's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=433.308-41.69
=391.6

Zylox-Tonbridge Medical Technology Co's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=433.308-41.69
=391.6

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €391.6 Mil mean?
Zylox-Tonbridge Medical Technology Co (FRA:818) has a Total Equity of €391.6 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Zylox-Tonbridge Medical Technology Co and its competitors.
Is Zylox-Tonbridge Medical Technology Co's Total Equity too high?
Zylox-Tonbridge Medical Technology Co's current Total Equity is €391.6 Mil. Overall, Zylox-Tonbridge Medical Technology Co has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zylox-Tonbridge Medical Technology Co's Total Equity compare to ABT and SYK?
Zylox-Tonbridge Medical Technology Co's Total Equity of €391.6 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Zylox-Tonbridge Medical Technology Co and its competitors. Zylox-Tonbridge Medical Technology Co's current Total Equity is €391.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zylox-Tonbridge Medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Zylox-Tonbridge Medical Technology Co (FRA:818) is currently considered Significantly Undervalued. The stock's GF Value™ is €3.72, compared to a current price of €2.08 — trading 44.1% below its estimated fair value. The current Total Equity is €391.6 Mil. Zylox-Tonbridge Medical Technology Co's overall GF Score™ is 76/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Zylox-Tonbridge Medical Technology Co (FRA:818), the current Total Equity is €391.6 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zylox-Tonbridge Medical Technology Co (FRA:818) Overvalued in 2026?

Based on GuruFocus' analysis, Zylox-Tonbridge Medical Technology Co stock appears to be undervalued. The current stock price of €2.08 is trading 44.1% below its estimated GF Value™ of €3.72. GuruFocus considers Zylox-Tonbridge Medical Technology Co to be Significantly Undervalued.

Key valuation signals for FRA:818:

  • Total Equity: €391.6 Mil
  • GF Value™: €3.72 vs. price of €2.08 (44.1% below fair value)
  • GF Score™: 76/100 with 5 warning signs

No single metric tells the full story. See the FRA:818 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zylox-Tonbridge Medical Technology Co Business Description

Other Exchanges 02190:Hong Kong
Address 270 Shuyun Road, Cangqian Street, Zylox-Tonbridge Industrial Park, Yuhang District, Zhejiang Province, Hangzhou, CHN
Zylox-Tonbridge Medical Technology Co Ltd is principally engaged in providing solutions to patients and physicians with a product portfolio covering peripheral-vascular interventional devices and neurovascular interventional devices in China and other countries. The company's products include Thrombite Clot Retriever Device (Thrombite CRD), Ultrafree Drug Coated PTA Balloon Catheter (Ultrafree DCB), and others. The company derives majority of its revenue from PRC.
76GF Score

Get the complete analysis for FRA:818

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.08
Price
€3.72
GF Value